No Data
No Data
Marinus Pharma Analyst Ratings
Catalyst Watch: Eyes on Tech With Apple, Amazon, Alphabet, and Meta Reporting
TD Cowen Downgrades Marinus Pharma to Hold
Marinus Pharmaceuticals Price Target Cut to $1.00/Share From $3.00 by RBC Capital
Express News | Cantor Fitzgerald Maintains Overweight on Marinus Pharma, Lowers Price Target to $4
Oppenheimer Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating
No Data
No Data